Repligen Corporation (NASDAQ:RGEN), a $9.36 billion market cap leader in bioprocessing technology, has been navigating a ...
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% year-over-year Achieved a nine-month book-to-bill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results